Search research articles
Contact Us
Filters
Showing results (1-10 of 26) with videos related to
Page
of 3
Sort By:
The New England Journal of Medicine
|
January 20, 2017
Myocarditis with Immune Checkpoint Blockade
Stéphane Ederhy, Anne-Laure Voisin, Stéphane Champiat
Drug Safety
|
October 21, 2019
Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study
Samy Babai, Anne-Laure Voisin, Célia Bertin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 2, 2020
Infectious complications in patients treated with immune checkpoint inhibitors
Jean-Denis Karam, Nicolas Noel, Anne-Laure Voisin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 19, 2017
Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication
Jean-Marie Michot, Parvady Ragou, Franck Carbonnel, et al.
Annals of the Rheumatic Diseases
|
March 20, 2020
Features of polymyalgia rheumatica-like syndrome after immune checkpoint inhibitor therapy
Gregoire Martin de Fremont, Rakiba Belkhir, Julien Henry, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2017
Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies
Alice Bernard-Tessier, Priscilla Jeanville, Stéphane Champiat, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2020
Letter responds to the comment in 'immune thrombocytopenia of haematological immune-related adverse events in cancer immunotherapy: Most and mighty'
Jean-Marie Michot, Julien Lazarovici, Ashley Tieu, et al.
Annals of the Rheumatic Diseases
|
March 1, 2017
Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy
Sébastien Le Burel, Stéphane Champiat, Emilie Routier, et al.
American Journal of Ophthalmology
|
February 18, 2019
Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy
Karen Bitton, Jean-Marie Michot, Emmanuel Barreau, et al.
Cancer Treatment Reviews
|
August 23, 2022
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias
Maria Kfoury, Marie Najean, Ariane Lappara, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 26) with videos related to
Sort By:
Page
of 3
The New England Journal of Medicine
|
January 20, 2017
Myocarditis with Immune Checkpoint Blockade
Stéphane Ederhy, Anne-Laure Voisin, Stéphane Champiat
Drug Safety
|
October 21, 2019
Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study
Samy Babai, Anne-Laure Voisin, Célia Bertin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 2, 2020
Infectious complications in patients treated with immune checkpoint inhibitors
Jean-Denis Karam, Nicolas Noel, Anne-Laure Voisin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 19, 2017
Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication
Jean-Marie Michot, Parvady Ragou, Franck Carbonnel, et al.
Annals of the Rheumatic Diseases
|
March 20, 2020
Features of polymyalgia rheumatica-like syndrome after immune checkpoint inhibitor therapy
Gregoire Martin de Fremont, Rakiba Belkhir, Julien Henry, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2017
Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies
Alice Bernard-Tessier, Priscilla Jeanville, Stéphane Champiat, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2020
Letter responds to the comment in 'immune thrombocytopenia of haematological immune-related adverse events in cancer immunotherapy: Most and mighty'
Jean-Marie Michot, Julien Lazarovici, Ashley Tieu, et al.
Annals of the Rheumatic Diseases
|
March 1, 2017
Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy
Sébastien Le Burel, Stéphane Champiat, Emilie Routier, et al.
American Journal of Ophthalmology
|
February 18, 2019
Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy
Karen Bitton, Jean-Marie Michot, Emmanuel Barreau, et al.
Cancer Treatment Reviews
|
August 23, 2022
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias
Maria Kfoury, Marie Najean, Ariane Lappara, et al.
Page
of 3